[Federal Register Volume 61, Number 109 (Wednesday, June 5, 1996)]
[Notices]
[Pages 28597-28598]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-14058]



-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE
Drug Enforcement Administration


Manufacturer of Controlled Substances; Correction

    On March 4, 1996, a Notice of Application for Johnson Matthey, Inc. 
(Johnson Matthey), Custom Pharmaceuticals Department, 2003 Nolte Drive, 
West Deptford, New Jersey 08066, was published in the Federal Register 
requesting registration as a bulk manufacturer of Schedules I and II 
controlled substances. See 61 FR 8303. The notice invited that comments 
or objections be filed by May 3, 1996. A correction was subsequently 
published on April 10, 1996, adding dihydrocodeine (9120) and 
meperidine (9230) to the list of controlled substances that Johnson 
Matthey made application to manufacture in bulk. See 61 FR 15974. 
Comments regarding Johnson Matthey's application for dihydrocodeine and 
meperidine must be filed by June 10, 1996.
    It has come to the Drug Enforcement Administration's (DEA) 
attention that Johnson Matthey does not wish to be registered as a bulk 
manufacturer of meperidine. Therefore, meperidine is hereby deleted 
from the list of controlled substances for which Johnson Matthey made 
application to manufacture in bulk. However, the list of controlled 
substances for which Johnson Matthey has applied to manufacture in bulk 
should have included thebaine (9333) and alfentanil (9737).

[[Page 28598]]

    Any other such applicant and any person who is presently registered 
with DEA to manufacture thebaine and alfentanil may file comments or 
objections to the issuance of the above application.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than (60 days from publication).

    Dated: May 28, 1996.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 96-14058 Filed 6-4-96; 8:45 am]
BILLING CODE 4410-09-M